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Fanconi anemia (FA) is an inherited DNA repair defi-
ciency syndrome. FA patients undergo progressive
bone marrow failure (BMF) during childhood, which
frequently requires allogeneic hematopoietic stem
cell transplantation. The pathogenesis of this BMF
has been elusive to date. Here we found that FA
patients exhibit a profound defect in hematopoietic
stem and progenitor cells (HSPCs) that is present
before the onset of clinical BMF. In response to
replicative stress and unresolved DNA damage,
p53 is hyperactivated in FA cells and triggers a
late p21Cdkn1a-dependent G0/G1 cell-cycle arrest.
Knockdown of p53 rescued the HSPC defects
observed in several in vitro and in vivo models,
including human FA or FA-like cells. Taken together,
our results identify an exacerbated p53/p21 ‘‘physio-
logical’’ response to cellular stress and DNA damage
accumulation as a central mechanism for progres-
sive HSPC elimination in FA patients, and have impli-
cations for clinical care.
INTRODUCTION
The hematopoietic system is tightly regulated to ensure the
constitution of a stem cell pool during embryonic development
and early postnatal life, and to maintain homeostasis throughout
adult life. Multiple extrinsic and intracellular signals are inte-36 Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc.grated in the hematopoietic stem and progenitor cells (HSPCs)
to regulate quiescence, self-renewal, and differentiation into
multiple lineages. Recently, the notion of crosstalk between
pathways regulating the hematopoietic homeostasis and the
DNA damage response (DDR) in HSPCs has emerged (Blanpain
et al., 2011; Rossi et al., 2008; Seita et al., 2010). Specifically,
there is substantial evidence that the tumor suppressor protein
p53, its transcriptional target p21CDKN1A/CIP1/WAF1, and other S
phase regulators play an important role in regulating HSPC exit
from the cell cycle, apoptosis, or DNA repair, depending on the
cellular context (Abbas and Dutta, 2009; Cheng et al., 2000;
Liu et al., 2009; Milyavsky et al., 2010; Mohrin et al., 2010; Viale
et al., 2009; Vousden and Prives, 2009). A p53-dependent
response to accumulation of DNA damage and cellular stress
has also been implicated in hematopoietic aging occurring
throughout life, both under physiological conditions and in
a number of DNA-repair-deficient in mice (Blanpain et al.,
2011; Niedernhofer, 2008; Nijnik et al., 2007; Rossi et al., 2007;
Zhang et al., 2005). Interestingly, impairment of these control
mechanisms can lead to genomic instability, progressive bone
marrow failure, and hematopoietic malignancies (Niedernhofer,
2008; Rossi et al., 2008).
Human acquired and inherited bone marrow failure (BMF)
disorders are characterized by pancytopenia and hypocellular
bone marrow occurring in patients during childhood. Although
acquired aplastic anemia has been related to autoimmune
mechanisms (Young, 2006), the pathophysiology of the most
frequent inherited BMF syndrome, Fanconi anemia (FA), is still
elusive (Dokal and Vulliamy, 2008; Shimamura and Alter, 2010).
FA is caused by biallelic mutations of 1 of the 15 FANC genes,
the products of which interact in the unique FA/BRCA pathway
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maintain genome integrity (de Winter and Joenje, 2009; Dokal
and Vulliamy, 2008; Moldovan and D’Andrea, 2009). Although
the precise biochemical functions of the FA/BRCA pathway are
still unclear, there is substantial evidence that it promotes proper
homologous recombination (HR)-mediated DNA repair (Deans
and West, 2011; Kee and D’Andrea, 2010). The FA/BRCA
pathway is also involved in the regulation of mitosis and cytoki-
nesis to prevent micronucleation and chromosome abnormali-
ties (Chan et al., 2009; Naim and Rosselli, 2009; Vinciguerra
et al., 2010). FA cells are also uniquely hypersensitive to oxida-
tive stress and apoptotic cytokine cues, including IFN-g and
TNF-a (Pang and Andreassen, 2009). FA cells show sponta-
neous and interstrand crosslinker-induced chromosome
fragility, a feature that is important for diagnosis in patients.
Patients with FA frequently display developmental abnormali-
ties, including short stature, a triangular face, and thumb
abnormalities (Dokal and Vulliamy, 2008; Shimamura and Alter,
2010). They undergo progressive BMF during childhood, which
frequently requires allogeneic hematopoietic stem cell (HSC)
transplant (Gluckman and Wagner, 2008; Kutler et al., 2003;
Shimamura and Alter, 2010). FA patients also experience a
strong predisposition to clonal evolution and cancer, especially
myelodysplasia (MDS) and acute myeloid leukemia (AML)
(Bagby and Meyers, 2007; Dokal and Vulliamy, 2008; Kutler
et al., 2003; Quentin et al., 2011; Soulier, 2011).
Attempts to uncover the mechanisms leading to BMF in FA
patients have been unsuccessful to date, largely because of
practical difficulties associated with studying a rare human
disorder with low bone marrow cells in patients, and because
murine Fanc/ models do not fully recapitulate the phenotype
of human FA (Parmar et al., 2009). The efficiency of allogeneic
HSC transplant in FA patients shows that BMF is primarily
related to an intrinsic defect of hematopoietic cells. Here, we
analyzed a large series of primary bone marrow samples from
FA patients and developed in vitro and in vivo functional models
to evaluate HSPC capacity in human FA cells. Consistent with
the constitutive DNA repair defect of FA cells and with a general
role of the p53 axis in HSC maintenance, we uncovered a
pathophysiological mechanism for BMF in Fanconi anemia, in
which HSPCs from FA patients are impaired due to p53/p21
activation and G0/G1 cell-cycle arrest in response to replicative
stress and the accumulation of DNA damage. We found that
this process begins prenatally during the formation of the
HSPC pool. Knockdown of p53 rescued the HSPC defects and
clonogenic ability in several in vitro and in vivo models, including
Fancd2/p53 mice and a xenograft model involving transfer of
human FA-like cord blood cells into immunodeficient mice. Our
data highlight the role of an exacerbated ‘‘physiological’’ DDR
due to a constitutive defect of DNA repair as a central mecha-
nism of BMF in FA patients. More generally, these findings
point to p53 activation due to unresolved cellular conflicts as a
common unifying signaling mechanism for BMF syndromes.
RESULTS
Progressive Impairment of HSPCs in FA Patients
To investigate BMF in FA, we analyzed bone marrow samples
from a cohort of 91 FA patients and compared them to samplesfrom 40 healthy donors. CD34+ cell numbers were lower in the
FA patients (Figure 1A), even in those who were diagnosed
before BMF onset (as in cases of FA siblings or severe congenital
syndrome). When evaluated by methylcellulose colony-forming
unit (CFU) assays, the clonogenicity of bulk bone marrow cells
or CD34+ cells for colony-forming unit granulocyte/macro-
phages (CFU-GMs) from the patients was very low to nondetect-
able (Figure 1B and Figure S1 available online). One feature of
FA is the possible onset of spontaneous genetic reversion in
hematopoietic cells, which can correct the FA phenotype and
lead to somatic mosaicism (Waisfisz et al., 1999; Soulier et al.,
2005). Interestingly, FA patients with somatic mosaicism from
our cohort (n = 9) had higher CD34+ cell counts and clonogenic-
ity, showing that reversion of the FA/BRCA pathway defect can
partially rescue hematopoiesis (Figures 1A and 1B).
We then ordered the CD34+ cell numbers in FA subjects and
healthy donors by age. Strikingly there was an additional
progressive, aged-related, decrease to almost zero CD34+
counts in FA subjects, but not in healthy donors, consistent
with the clinical worsening of the BMF during childhood (Figures
1C and 1D).
Collectively, these data suggest that FA subjects have an
impairment of hematopoiesis that begins early, worsens through
life, and results in overt BMF during childhood.
Constitutive Induction of p53 in FA Cells
FA cells have an intrinsic defect in the FA/BRCA pathway that
is involved in the cellular response to DNA damage, particularly
during DNA replication and mitosis (Chan et al., 2009; de
Winter and Joenje, 2009; Moldovan and D’Andrea, 2009;
Naim and Rosselli, 2009; Pang and Andreassen, 2009; Vinci-
guerra et al., 2010). The progressive BMF seen in FA patients
suggests that accumulation of endogenous stress and DNA
damage participates in hematopoietic impairment. The protein
p53 plays a central role in the response to stress and DNA
damage and it has been indicated to be involved in HSPC
maintenance (Blanpain et al., 2011; Milyavsky et al., 2010;
Rossi et al., 2008; Vousden and Prives, 2009). Overexpression
of p53 has been reported in FA Epstein-Barr virus (EBV)-
immortalized cell lines and mouse cells, but a clear link to
BMF has not been established (Kruyt et al., 1996; Kupfer and
D’Andrea, 1996; Freie et al., 2003; Zhang et al., 2007). Here,
we analyzed p53 activation in primary FA samples and found
strong basal and Mitomycin C (MMC)-induced p53 protein
expression in primary blood cells from 11 unrelated FA
patients, primary skin fibroblasts from 2 FA patients, and
bone marrow cells from Fancg/ mice (Figure 2A). Moreover,
we found a spontaneous increase in p53 staining in primary
bone marrow cells from seven FA patients as compared with
three healthy donors (Figure 2B). Of note, oxidative stress
also strongly induced p53 in FA cells (Zhang et al., 2005). To
confirm that the p53 induction was directly related to the
FA/BRCA pathway defect, we designed FA-like human 293T
cells using short hairpin RNA (shRNA)-mediated knockdown
of FANCD2, a key target of the FA pathway, and observed
p53 as well as p21 induction in these cells (Figure 2C). In addi-
tion, we also observed hyperactivation of p53 in murine
Fancd2/ bone marrow cells in the presence or absence of
exogenous DNA damage (Figure 2D).Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc. 37
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Figure 1. Impairment of HSPCs and Their Worsening with Age in FA Patients
(A) CD34+ cell percentages in fresh bone marrow samples of 82 FA patients (FA), 9 FA patients with genetic reversion and somatic mosaicism (Rev), and 40 non-
FA healthy donors. Mean values are indicated by horizontal bars. Statistical analyses were performed using the Wilcoxon test (FA versus healthy donors, *p <
1015; FA versus Rev, p < 104; Rev versus healthy donors, nonsignificant). (B) CFU-GM assays (CFU) using fresh bone marrow cells from 47 FA patients, 9 Rev
patients, and 40 healthy donors (FA versus donors, *p < 1015; FA versus Rev, p < 103; Rev versus donors, p < 104). (C) Bone marrow CD34+ cell percentages
according to age in FA patients (n = 82) and (D) healthy donors (n = 40). For clarity, data from FA patients with genetic reversion (somatic mosaicism) are not
indicated here. The dashed line indicates the median value in FA patients (0.40%) and in healthy donors (1.75%), and the solid line indicates the trend according
to aging. See also Figure S1.
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p53/p21-Mediated Bone Marrow Failure in FAp53/p21 Activation Due to Unresolved DNA Damage
Triggers a Late G0/G1 Cell-Cycle Arrest in FA Cells
after Resolution of an Early G2 Arrest
To mimic the response of FA cells to endogenous DNA damage
and to analyze a potential link to the progressive cell impairment
observed in patients, we briefly exposed EBV-immortalized FA
cells to interstrand crosslinking agents (MMC) and analyzed
the cellular response at several time points. Non-FA controls
cells were largely unaffected by the MMC pulse, but FA cells
displayed a classical excess G2 arrest at 24 hr (Figure 3A) (Sey-
schab et al., 1993). Strikingly, at later time points, we noticed
that the G2 arrest resolved and the cells shifted into G0/G1
with S phase extinction (Figure 3A). This phenotype was only
observed in FA cells, together with a strong p53 and p21 induc-
tion (Figures 3A and 3B). To investigate the consequences of
p53 induction in FA cells, we knocked down p53 using shRNA
(Figures 3C–3H). We found that p53 depletion in FA cells limited
the level of growth inhibition elicited by a brief exposure to MMC
(Figure 3C). This change was not caused by inhibition of the early
G2 arrest or apoptosis (Figure 3D and Figure S2A). However, in
p53-silenced FA cells, p21 induction, G0/G1 accumulation,
and inhibition of BrdU incorporation were less marked relative
to control FA cells, while genomic instability was dramatically
increased (Figures 3D–3H). Consistently, large-scale gene38 Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc.expression analysis of p53-silenced cells relative to control FA
cells 72 hr after the MMC pulse identified a cell-cycle arrest
signature that was diminished by p53 silencing (Figure 3I). In
addition, chromatin immunoprecipitation (ChIP) experiments in
FA cells showed that p53 was preferentially recruited to the
promoters of p21 (CDKN1A) and GADD45a, two genes involved
in G0/G1 cell-cycle arrest, but not those of BAX, a gene control-
ling apoptosis, in agreement with a low level of apoptosis in
these EBV-immortalized cells (Figures S2A and S2B).
Collectively, these data suggest that unresolved DNA
damage in FA cells induces a p53/p21 response that restricts
the cell cycle to G0/G1 after resolution of the G2 arrest, to limit
deleterious DNA damage accumulation and preserve the
genome integrity. Depletion of p53 partially rescues this pheno-
type by allowing a fraction of the cells to cycle and undergo
replication, despite the increased genomic instability and G2
accumulation.
Fanc–/– Mice Have HSPC Defects that Are Rescued
by p53 Silencing
To further investigate the BMFmechanisms in FA, we performed
experiments on two different FA mouse lines, Fancg/ and
Fancd2/. Although these mice do not develop spontaneous
BMF, they exhibit subtle HSC defects (Barroca et al., 2011;
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Figure 2. Constitutive p53 Induction in FA Cells
(A) Representative immunoblot analysis of phytohemagglutinin-stimulated blood lymphocytes (PHA-PBL, top panel; PHA-PBL from 11 FA patients were tested
with consistent results) and primary fibroblasts (fibro FANCA) from FA patients, and bone marrow cells of Fancg/ mice. Controls were PHA-PBL from healthy
donors (Non-FA), FANCA-deficient human fibroblasts that were corrected by retroviral complementation (+FA-A), and wild-type (WT) littermate mice. Cells were
cultured with increasing concentrations of Mitomycin C (MMC) as indicated.
(B) Top panel: Quantification of p53 fluorescence signal in individual bone marrow cells. Each circle represents a single cell; data from three representative FA
patients (referred by unique EGF identification number) and a healthy donor are shown. Lower panel: Representative microscopy images of p53 staining. Circles
indicate nuclear contours; mean values are indicated by a horizontal bar and statistical analyses were performed using the Student test (*p < 104, 104, and 102
in healthy donor versus FA patient EGF243, EGF089, and EGF189, respectively). A.U., arbitrary unit; original magnification, 633.
(C) Immunoblot analysis of p53 and p21 protein levels in human 293T cells after transduction with Ctrl or FANCD2 shRNAs.
(D) Immunoblot analysis of phospho-S15-p53 and p21 protein levels in murine wild-type (WT) and Fancd2/ bone marrow cells. Cells were irradiated as
indicated.
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p53/p21-Mediated Bone Marrow Failure in FAParmar et al., 2010). We investigated whether the p53 response
in FA cells could influence HSC capacity in these mice. First, we
generated double knockout Fancd2/p53/ mice and
analyzed their HSPCs. Strikingly, knockdown of p53 rescued
the HSC defects of Fancd2/ mice with respect to LinSca-
1+c-Kit+ (LSK) cell numbers, clonogenicity, and proliferative
and survival potential (Figures 4A and 4B). Second, we per-
formed engraftment experiments using Fancg/ bone marrow
cells (Figure S3). Lin cells were transduced with either control
or p53 and shRNAs and subsequently reinjected in sublethally
irradiated syngenic wild-type mice (Figure S3A). We also de-
signed a competitive engraftment assay in which Fancg/
bone marrow Lin cells were transduced with a control-Cherry
or p53-GFP shRNA, sorted based on Cherry/GFP expression,
and cotransplanted (Figure S3B). In both experimental settings,
p53-silenced cells engrafted better than controls (Figure S3).
We and others recently reported a role of the FA/BRCA
pathway in monitoring cell cycle progression through mitosis
and cytokinesis (Chan et al., 2009; Naim and Rosselli, 2009; Vin-ciguerra et al., 2010). Consistent with our previous study, murine
Fancd2/ bone marrow LSK cells exhibited a high rate of binu-
cleated cells and apoptosis, a hallmark of cytokinesis failure
(Figures 4C and 4D). These abnormalities were rescued in
Fancd2/p53/mice, showing that the cytokinesis failure
observed was p53 dependent (Figures 4C and 4D). Moreover,
we exposed Fancd2/lin bone marrow cells to a cytokinesis
inhibitor (VX-680) and found that such cells are hypersensitive
compared to non-FA controls, again in a p53-dependent manner
(Figure 4E and Figure S4).
Taken together, these experiments show that p53 impairs the
hematopoietic and mitotic potential of Fanc-deficient murine
HSPCs.
Silencing p53/p21 Expression Rescues Human FA
HSPCs Capacities in In Vitro and In Vivo Models
We next investigated whether inhibition of the p53/p21 response
could improve HSPC function in human FA cells. CD34+ cells
were sorted from fresh bone marrow samples from FA patientsCell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc. 39
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Figure 3. Unresolved DNA Damage Triggers a p53/p21 Response that Restricts the Cell Cycle to G0/G1 in FA Cells
(A) Cell-cycle analysis in FA EBV cells relative to non-FA EBV cells. After MMC pulse, FA cells displayed an early FA-prototypical arrest in G2. At later time
points and after resolution of the G2 checkpoint, FA cells shifted to arrest in G0/G1 with S phase extinction. G0/G1-S-G2 relative percentages are indicated for
each panel.
(B) p53, phospho-S15-p53, and p21 immunoblot analyses of FA and non-FA cell extracts at several time points after the MMC pulse.
(C) FA EBV cell lines were transduced with Ctrl or p53 shRNAs, and GFP+ cells were sorted, cultured for 24 hr, and grown for 3 days in MMC-free medium after
an MMC pulse. Live cell numbers are shown at time points 0, 24, 48, and 72 hr. A non-FA EBV cell line transduced with Ctrl or p53 shRNA is shown as control.
In the absence of MMC pulse, Ctrl- or p53-shRNA-transduced cell growth did not differ (not shown).
(D) Cell-cycle analysis of FA cells shows a prototypical arrest in G2 of both Ctrl- and p53-shRNA-transduced cells. G0/G1-S-G2 relative percentages are indicated
for each panel.
(E) Percentage of Ki67 cells in FA EBV cells transduced with Ctrl and p53 shRNA at 0 hr and 72 hr after MMC pulse. Statistical analyses were performed using
the Chi-squared test for trend in proportions (*p < 106).
(F) p53, phospho-S15-p53 (pS15p53, activated), p21CDKN1A/CIP1/WAF1, and actin (loading control) immunoblot analyses of Ctrl- and p53-shRNA-transduced
EBV FA-cell extracts.
(G) Quantification of the fraction of cycling Ctrl- and p53-shRNA-transduced FA cells by BrdU incorporation. The strongly decreased percentages of cells in
S phase after MMC treatment were lower in p53-shRNA-transduced cells; statistical analyses were performed using the Odd ratio test (*p < 104). FA tests
were performed in triplicates in at least two EBV FA cell lines.
(H) Quantification of the genomic instability (chromosomal breaks per mitosis) in Ctrl- and p53-shRNA-transduced EBV FA-cells. Statistical analyses were
performed using the Chi-squared test for trend in proportions (*p < 1012).
(I) Top-ranked biological pathways that were differentially expressed in p53- relative to Ctrl-shRNA-transduced EBV FA-cells at 72 hr; significance values were
determined by the hypergeometrical test using the 188 most differentially expressed genes between p53-silenced and control cells.
See also Figure S2.
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p53/p21-Mediated Bone Marrow Failure in FAand lentivirally transduced with shRNA. Strikingly, depletion of
p53 or p21 dramatically rescued in vitro clonogenicity of FA
patients’ CD34+ cells in CFU-GM assays (Figures 5A and 5B;
Table S1). Then, because the very low CD34+ cell numbers in
FA patients did not allow efficient xenotransplant experiments,
we used a surrogate model to analyze clonogenicity in vivo.
We designed a xenotransplant assay using normal human cord40 Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc.blood CD34+ cells that were transduced with either a shRNA
against FANCD2 (to obtain FA-like cells) or a tandem shRNA
against FANCD2-TP53 (to simultaneously deplete FANCD2
and p53), and xenotransplanted them into Nod/Scid/IL2-R gc
null (NSG) immunodeficient mice (Figure 5C). Strikingly, p53-
silenced FA-like CD34+ cells engrafted dramatically better than
the control FA-like cells (Figures 5D and 5E). Collectively, these
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(B) Analysis of clonal growth of murine bone marrow HSPCs as determined by proliferation of isolated LSK cells in vitro for 2 weeks in presence of TPO and
SCF (left panel), and Cobblestone area-forming cell (CAFC) frequencies of total bone marrow cells on FBMD1 stroma cells by day 28 (right panel). The data are
means from three mice per group; statistical analyses were performed using the t test (for proliferation, *p < 102 WT versus Fancd2/ and Fancd2/ versus
Fancd2/p53/; p < 0.05 WT versus Fancd2/p53/; for CAFC count, p < 0.05 WT versus Fancd2/ and p < 102 Fancd2/ versus Fancd2/p53/; WT
versus Fancd2/p53/, nonsignificant).
(C) Frequencies of binucleated cells in proliferating HSPCs. Bonemarrow LSK cells were grown in culture for 48–72 hr and stained for microtubules (red), nuclear
membrane Lap2 (green), and DNA (blue) to determine the frequencies of binucleated cells. Representative images of binucleated LSK cells are shown in the left
panel with original magnification of 633. The data in the right panel are means from four mice per group; statistical analyses were performed using the t test (*p <
103 WT versus Fancd2/ and p < 102 Fancd2/ versus Fancd2/p53/; WT versus Fancd2/p53/, nonsignificant).
(D) Apoptosis of the bone marrow HSPCs as determined by Annexin V staining. Data are means from three mice per group; statistical analyses were performed
using the t test (*p < 0.05 WT versus Fancd2/ and Fancd2/ versus Fancd2/p53/; WT versus Fancd2/p53/, nonsignificant).
(E) Survival of bone marrow in the presence of the cytokinesis inhibitor VX-680. Lin cells from the bone marrow were cultured and exposed to VX-680 for 72 hr,
and cell survival was determined by a count of live cells. The data are means from three or four mice per group.
See also Figures S3 and S4.
Cell Stem Cell
p53/p21-Mediated Bone Marrow Failure in FAdata demonstrate that the p53/p21 axis impairs the in vitro and
in vivo clonogenicity of human FA HSPCs.
G0/G1 Cell-Cycle Arrest and S Phase Extinction
in FA HSPCs
We then evaluated the cell cycle in HSPCs from FA patients.
Fresh, untreated CD34+ cells from six FA patients and two
healthy donors were analyzed; strikingly, the percentage of cells
in G0/G1 was higher in FA than in controls (Figure 6A). Moreover,total bone marrow cells from FA patients were massively ar-
rested in G0/G1 and they showed a spontaneous increase of
gH2AX staining (Figures 6B and 6C).To overcome the practical
issues related to the rarity of CD34+ cells in FA patients, we
used healthy human CD34+ cells transduced with FANCD2
shRNA and tested whether the accumulation of DNA damage
can trigger G0/G1 cell-cycle arrest in these human FA-like
HSPCs. We sorted CD34+ cells from human cord blood and
stimulated them to enter into S phase in ex vivo cultureCell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc. 41
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Figure 5. Silencing p53/p21 Expression Rescues FA Hematopoietic Progenitor Cell Capacities in Human In Vitro and In Vivo Models
(A) CFU-GM assays using Ctrl- or p53-shRNA-transduced CD34+ bonemarrow cells from 14 FA patients. Colonies were counted 14 days after plating 500 CD34+
cells/well in 6-well plates, in duplicates. Mean values are indicated by horizontal bars. Statistical analyses were performed using the Wilcoxon test (*p < 104).
Complete data, and data from p21-silenced cells, are shown in Table S1.
(B) Representative examples of CFU-GM-derived colonies from CD34+ cells of a given FA patient. Horizontal bar size = 1,000 mm.
(C) Design of human FA-like cell xenotransplant experiments. Human cord blood CD34+ cells were transduced overnight with FANCD2-GFP shRNA or tandem
FANCD2-TP53-GFP shRNA and injected into sublethally irradiated immunodeficient Nod/Scid/IL2-R gc null (NSG) mice. Immunoblot shows FANCD2 and p53
silencing efficiency.
(D) Representative flow cytometry analysis of the proportion of donor human cells in mouse peripheral blood as quantified by HuCD45 staining 5 weeks
posttransplant. The percentage of blood donor GFP+ cells (transduced cells) is indicated.
(E) Chimerism postxenotransplant of FANCD2- or tandem FANCD2-TP53-shRNA-transduced human cord blood CD34+ cells, as assessed by GFP+ cell
percentages on blood cell (5 weeks posttransplant, left panel) and bone marrow cell (16 weeks posttransplant, right panel). Each circle represents data from one
mouse. Mean values are indicated by horizontal bars. Statistical analysis was performed using theWilcoxon test (*p = 102 at 5 weeks posttransplant; p < 102, at
16 weeks posttransplant,).
See also Table S1.
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p53/p21-Mediated Bone Marrow Failure in FA(Figure 6D). Then, cells were transduced with control or FANCD2
shRNA, GFP sorted, and briefly exposed to MMC. The control
cells progressed through the cell cycle, but the FA-like CD34+
cells arrested in G0/G1 with S phase extinction, along with
gH2AX and 53BP1 accumulation (Figures 6D–6G).
p21 Expression and Cell-Cycle Arrest in Embryonic
and Adult HSPCs from FA Patients
To confirm that FA patients have constitutive activation of
a p53/p21 axis in their HSPCs in vivo (in addition to increased
p53 in total bonemarrow cells, Figure 2B), we evaluated the level42 Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc.of the p21 gene expression by RT-qPCR in CD34+ cells sorted
from fresh bone marrow samples of FA patients and healthy
donors. We found that p21 levels were higher in FA CD34+ cells
(Figure 7A). We analyzed large-scale gene expression data of
bone marrow cells from FA patients versus healthy donors.
Gene pathways enrichment analysis ranked on top position
signatures of cell-cycle and mitosis arrest (Figures 7B and 7C),
consistent with increased numbers of G0/G1 cell-cycle-arrested
cells in the bone marrow of FA patients. Notably, not only p21,
but also other cell cycle inhibitors like p16 (CDKN2A) were
induced in total bone marrow cells from FA patients (Figure 6C),
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Figure 6. G0/G1 Cell-Cycle Arrest in FA HSPCs
(A) Percentage of cell cycle phases in the bone marrow CD34+ cells from six FA patients and two healthy donors (*p < 104 for G0/G1; p < 104 for S/G2-M). Data
in healthy donors were consistent with previous reports (Gothot et al., 1997).
(B) Percentage of Ki67 cells in fresh bone marrow cells from three FA patients and two healthy controls (*p < 104); representative microscopy images for Ki67
staining are shown.
(C) Percentage of bone marrow cells positive for gH2AX staining (at least one foci) in five FA patients and two healthy donors (*p < 102); representative
microscopy images for gH2AX staining are shown.
(D) Healthy human cord blood CD34+ cells were stimulated via cytokines to enter the cell cycle. After 24 hr, cells were transduced by FANCD2 or Ctrl shRNA.
Three days later, GFP+ cells were sorted, briefly exposed to MMC (2 hr at 100 ng/ml), grown for 5 days in MMC-free medium, and analyzed for cell cycle and
proliferation. Cell-cycle analysis is shown at time point D5; G0/G1-S-G2 relative percentages are indicated for each condition.
(E) Percentage of Ki67 cells from the experiment shown in (D) at D5 (*p < 104).
(F) Percentage of gH2AX+ and 53BP1+ cells (*p < 106 for gH2AX, and p < 105 for 53BP1).
(G) Percentage of gH2AX+ cells within the Ki67 population. Data of (A), left panels of (D), and (G) were obtained by flow cytometry. Original magnification of
microscopy images, 633.
For (A), (B), (C), (E) and (F), the mean value is shown; statistical analyses were performed using the Chi-squared test for trend in proportions.
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Figure 7. p21 Expression and Cell-Cycle Arrest in Embryonic and Adult HSPCs from FA Patients
(A) p21 (CDKN1A) gene expression was analyzed by RT-qPCR in bone marrow CD34+ cells from 13 FA patients and 3 healthy donors. Normalization was
performed using the GUS reference gene. p21 values are expressed by fold change relative to the mean expression in healthy donors, which was arbitrary
attributed to 1. Mean values are indicated by a horizontal bar. Statistical analyses were performed using the Wilcoxon test (*p < 102).
(B) Top-ranked differentially expressed biological processes between FA and non-FA bulk bone marrow samples. Gene Ontology genesets were scored using
the Gene Set Enrichment Analysis (GSEA) and p values were computed using 2,000 permutations. The top-ranked GO biological processes are shown.
(C) Hierarchical clustering and heat-map of gene expression in FA and non-FA bone marrow samples using the geneset G1_S_TRANSITION_OF_ MITOTIC_
CELL_CYCLE.
(D) p21 gene expression was analyzed by RT-qPCR in liver samples from four human FA fetuses and compared to six non-FA fetuses from the same term
(14–18 weeks of gestation). Normalization and representation of the expression data was performed as in (A). Statistical analyses were performed using the
Student test (*p < 103). For both (A) and (D), RT-qPCR analyses were performed in an independent set of experiments and normalized to the expression of
a second reference gene (ABL1) with consistent results (data not shown).
(E) A model for BMF in FA.
Cell Stem Cell
p53/p21-Mediated Bone Marrow Failure in FAwhereas in CD34+ purified cells, p16 expression was undetect-
able (by RT-qPCR experiments; data not shown), suggesting
that the downstream pathways may vary between HSPCs and
more differentiated hematopoietic progenitor cells in patients
(Blanpain et al., 2011).
Our data in bone marrow HSPCs from very young FA patients
(Figure 1C) suggested that the hematopoietic impairment
begins early in life. It is noteworthy that the formation of the
hematopoietic stem cell (HSC) pool occurs largely during
prenatal life, more specifically in human in the embryonic liver
between 14 and 18 weeks of gestation. We hypothesized that
such cells should experience massive replicative stress during
the expansion stage, leading to an activation of the p53/p21
axis in FA subjects. We analyzed p21 gene expression in four
FA fetal liver samples obtained between 14 and 18 weeks of
gestation from medical abortion after FA prenatal diagnosis.44 Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc.Compared to six non-FA fetal liver samples from the same
gestational stage, p21 levels were dramatically overexpressed
in the FA fetus (Figure 7D). Taken together with our other data,
this suggests that replicative stress triggers an exacerbated
p53/p21 response that impairs the HSC pool during prenatal
life in FA subjects. Additional progressive aged-related cellular
stress and DNA damage would lead to HSPC exhaustion and
BMF during childhood.
DISCUSSION
Although FA is the most frequent cause of inherited BMF, its
pathophysiological mechanisms have been elusive to date.
Research has been hampered by the fact that Fanc-deficient
mice do not spontaneously develop BMF (Parmar et al., 2009).
Here we investigated primary bonemarrow samples from a large
Cell Stem Cell
p53/p21-Mediated Bone Marrow Failure in FAseries of FA patients and found a contitutive activation of a
p53/p21 axis in FA HSPCs. This response was triggered in
FA cells by unresolved cellular stress and DNA damage and
leads to a G0/G1 cell-cycle arrest after resolution of the early
G2-arrest. The link with the development of an overt BMF in
patients was shown using several in vitro and in vivo models,
including an experimental protocol using FA-like cells that
overcomes the practical difficulties associated with the lack of
CD34+ cells from FA patients. Moreover, our data in very young
FA subjects (before the development of a clinical BMF) and in
human FA fetus strongly suggest that this process begins as
early as prenatally during the formation of the HSC pool.
The protein p53 is a key transcription factor that regulates
several signaling pathways involved in the response to physio-
logical signals, cellular stress, DNA damage, and oncogene
activation (Vousden and Prives, 2009). When activated, p53
accumulates and triggers expression of target genes that
protect genomic integrity. These protective mechanisms include
cell-cycle arrest and quiescence, DNA repair, initiation of senes-
cence, or induction of apoptosis, depending on the cellular
context (Blanpain et al., 2011; Rossi et al., 2008; Vousden and
Prives, 2009). FA patients have a constitutive defect in the FA/
BRCA pathway, leading to accumulation of replicative DNA
damage, cytokinesis failure, and cellular stress (e.g., via ROS
and TNF-a) (Chan et al., 2009; Dufour et al., 2003; Moldovan
and D’Andrea, 2009; Naim and Rosselli, 2009; Pang and An-
dreassen, 2009; Vinciguerra et al., 2010; Zhang et al., 2005).
The activation of the p53/p21 axis that we found in the HSPCs
from FA patients is likely an exacerbated physiological response
to unresolved replication stress, endogenous DNA damage, and
cellular stress that accumulate throughout accelerated aging in
FA (Neveling et al., 2009; Rossi et al., 2008). Such progressive
impairment of HSPCs by p53-related cell-cycle arrest and
apoptosis is consistent with the delayed onset and progressive
feature of the BMF seen in FA patients. Our findings that very
young FA patients exhibit an HSPC defect before the develop-
ment of a clinical BMF and that the p53/p21 axis is activated in
human fetal liver samples at the stage of massive HSC pool
expansion suggest a model for BMF throughout life (Figure 7E).
In this model, the formation of the HSC pool during fetal liver
development is hampered by replicative stress; after birth, the
additional accumulation of cellular stress and unresolved DNA
damage leads to progressive exhaustion of the remaining
HSCs and clinical BMF.
Our findings have implications for the clinical care and thera-
peutic of FA patients. First, because excess cellular stress and
unresolved DNA damage accumulating throughout life trigger
HSPC impairment through p53/p21 induction, it would be bene-
ficial to limit such accumulation. In addition to benefiting from
the prevention of exposure to exogenous DNA insults, patients
might therefore benefit from new treatments aiming to inhibit
proinflammatory cytokines or oxidative stress (Dufour and
Svahn, 2008). Interestingly, it was recently shown that the FA/
BRCA pathway counteracts the DNA interstrand crosslink geno-
toxicity related to endogeneous aldehydes (by-products of
cellular metabolism), and BMF might be mitigated if patients’
capacity for detoxifying aldehydes could be enhanced (Joenje,
2011; Langevin et al., 2011). Second, although direct targeting
of p53 using small inhibitors (Gudkov and Komarova, 2010)might enhance HSPC progression through the cell cycle and
ameliorate BMF, this approach would probably increase
genomic instability and increase the risk of clonal evolution to
malignancy. Third, regarding gene therapy, which constitutes
a promising option for FA patients (Tolar et al., 2011), our data
suggest that HSPCs would need to be collected at as early an
age as possible to avoid accumulation of damage and exhaus-
tion. More generally, whatever therapeutic options are pursued,
it is likely that they will be more effective if started early in life.
Finally, these concepts reinforce the view that allogeneic bone
marrow transplant is a radical and curative therapy for BMF in
FA patients, despite the risk of early and late complications
(Gluckman and Wagner, 2008; Rosenberg et al., 2005).
A key feature of FA is a major predisposition to MDS and AML
(Dokal and Vulliamy, 2008; Kutler et al., 2003; Quentin et al.,
2011; Shimamura and Alter, 2010). FA patients frequently expe-
rience genetic clonal evolution, which can lead to transformation
in a multistep, oncogenic manner. Interestingly, transformed FA
cells frequently acquire attenuation of the response to DNA
damage and cellular stress, suggesting that p53 induction in
FA constitutes an anticancer barrier that has to be overcome
during tumor progression (Ceccaldi et al., 2011; Li et al., 2007;
Rani et al., 2008). In addition to DDR attenuation, we also found
rare cases of p53 deletion in AML developing in FA patients (Fig-
ure S5). These concepts have important implications for the
development of MDS/AML treatments based on synthetic
lethality by the targeting of specific DDR pathways in FA patients
and, more generally, in non-FA patients (Chen et al., 2009; Helle-
day et al., 2008; Jiang et al., 2009).
FA is the most frequent inherited cause of BMF (Dokal and
Vulliamy, 2008; Shimamura and Alter, 2010). Interestingly, an
elevated p53 response has been implicated in the pathogenesis
of other inherited BMF syndromes. In Diamond Blackfan
anemia (DBA), a defect in ribosome metabolism induces
a p53-dependent response in the highly proliferative erythroid
compartment, leading to massive apoptosis and neonatal
anemia (Narla and Ebert, 2010; Zhang and Lu, 2009). In dysker-
atosis congenita, a defect in telomere metabolism and subse-
quent progressive telomere shortening triggers p53-induced
senescence, leading to a delayed BMF in patients (Bellodi
et al., 2010; Chin et al., 1999). Our findings in FA point to the
idea that p53 activation due to unresolved cellular conflicts
may be a common unifying signaling mechanism for inherited
BMF syndromes.
EXPERIMENTAL PROCEDURES
Patients and Biological Material Collection
This study was based on the cohort of FA patients referred at Saint-Louis and
Robert Debre´ Hospitals, Paris, French Reference Center for Constitutional
Bone Marrow Failure. All patients had an FA diagnosis based on FA tests,
including the chromosomal breakage test (Soulier et al., 2005). Informed
consent was obtained from the patients and/or their relatives. The study was
approved by the Institutional Review Board of Institut Universitaire d’He´mato-
logie at Saint-Louis Hospital, Paris. Biological samples from 91 FA patients,
aged 1 to 40 years (median 10), were available from yearly FA follow-up.
Samples from 40 healthy bone marrow donors, aged 4 to 48 years (median
26), were used as controls (Cell Therapy Unit, Hopital Saint-Louis). CD34+ cells
from fresh bone marrow samples were purified using the MicroBead kit
(Miltenyi). EBV-immortalized lymphoblast cell lines from FA patients were
produced in our center and used at low passage. Human umbilical cord bloodCell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc. 45
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p53/p21-Mediated Bone Marrow Failure in FAsamples were collected from healthy full-term deliveries after maternal
informed consent according to French authorities guidelines. FA fetus samples
were obtained after medical abortion for FA prenatal diagnosis at 14–18 weeks
of gestation; non-FA controls were fetus samples of the same term diagnosed
with nonrelevant malformations. All fetus samples were obtained with written
consent of the parents for research.
Functional In Vitro Tests in EBV Cells
After lentiviral transduction of shRNA in FA EBV cell lines, GFP+ cells were
sorted and cultured. The FA tests were performed, in triplicates, after 2 hr
MMC pulse (100 ng/ml) on growing cells, on at least two different EBV FA
cell lines, in at least two independent experiments. For cell-cycle analysis, cells
were treated with MMC, washed, and cultured in MMC-free medium. At the
indicated time points, cells were fixed in chilled 70% ethanol, stored overnight
at 20C, washed with PBS, and resuspended in propidium iodide. For BrdU
experiments, cells were incubated with a 5-bromo-20-deoxy-uridine (BrdU)
pulse (10 mg/ml) for 45 min at each time point. Then, cells were washed and
resuspended in culture medium for 2 hr prior to fixation in chilled 70% ethanol.
Ratios of cycling cell were analyzed by FACS. Chromosomal break tests were
scored on mitoses using conventional cytogenetic methods (Soulier et al.,
2005).
Immunoblotting and Immunofluorescent Analyses
Antibodies were used against human p53 (D0-1, Santa Cruz), pSer15p53 (Cell
Signaling), murine p53 (Calbiochem, clone PAb240), murine pSer15p53
(Calbiochem), Actin (Santa Cruz), human FANCD2 (Novus Biologicals), mouse
Fancd2 (Parmar et al., 2010), p21 (Becton Dickinson), and vinculin (Abcam).
Signals were detected using an enhanced chemiluminescence (ECL) kit
(Pierce) and visualized with a Fuji LAS-3000 luminescent image analyzer
system.
For immunofluorescent analysis, HSPCs were cytospun on slides, fixed,
permeabilized, and subsequently stained for Ki67 (Abcam), gH2AX (Millipore),
53BP1 (Cell Signaling), and p53 (D0-1, Santa Cruz).
ChIP Assay
ChIP was performed using the p53 monoclonal antibody D0-1 (Santa Cruz) as
described (Jackson and Pereira-Smith, 2006).
Murine Bone Marrow Analysis
Fancg/ mice were a kind gift of F. Arwert (Koomen et al., 2002). Fancd2/
mice and Fancd2/p53/ mice were generated as previously reported
(Houghtaling et al., 2003, 2005; Parmar et al., 2010). Murine bone marrow cells
were harvested and stained for LSK cells as previously described (Parmar
et al., 2010). For apoptosis detection, cells were stained with FITC-Annexin
V (BD Biosciences), and data were analyzed using FlowJo software. LSK cells
were FACS sorted and cultured in StemPro HSC medium (GIBCO, Invitrogen)
containing 40 ng/ml each murine stem cell factor (SCF) and murine thrombo-
poietin (TPO). For quantitation of binucleated cells, LSK cells were allowed
to proliferate for 48–72 hr and cytospun on slides. The cells were then fixed
and permeabilized, and subsequently stained for microtubules, DNA, and
nuclear membrane Lap2 as described previously (Vinciguerra et al., 2010).
To assess the toxicity of cytokinesis inhibition on bone marrow, Lin cells
were isolated using magnetic beads (Miltenyi) and cultured in the presence
of the VX-680 cytokinesis inhibitor (ChemieTek) in HSC medium. Cell survival
was assessed by a count of the live cells using Trypan blue staining.
Gene Silencing in Human and Murine Hematopoietic Cells
shRNAs targeting human FANCD2 (Ceccaldi et al., 2011), TP53 (Brummel-
kamp et al., 2002), p21 (Berns et al., 2004), murine Trp53 (Dirac and Bernards,
2003), and Luc (Ctrl) were generated in the pTRIP/DU3-MND-GFP vector and
transduced using lentivirus. The vector used to construct the tandem
FANCD2-TP53 shRNA is a kind gift of Bruno Verhasselt (Ghent University
Hospital, Belgium). A vector encoding the red fluorescent protein Cherry
was derived from pTRIP/DU3-MND-GFP and a shRNA Luc was inserted. Cells
were cultured in RPMI supplemented with 20% BIT (Stem Cell Technologies),
stem cell factor, Flt3-ligand, IL-3 (R&D Systems Europe), and thrombopoietin
(Stem Cell Technologies). Silencing efficiency was checked by specific immu-
noblot in all experiments.46 Cell Stem Cell 11, 36–49, July 6, 2012 ª2012 Elsevier Inc.CFU-GM Assays and CAFC Assays
To evaluate CFU-GM colony numbers in human samples, 53104 bulk bone
marrow cells were plated in duplicate and cultured in MethoCult medium
(Stem Cell Technologies) in 6-plate dishes. On day 14, CFU-GMs were identi-
fied and counted using standard criteria. For CFU-GM assay combined with
shRNA silencing, 500 CD34+ cells from FA patients were transduced overnight
with Ctrl, p53, or p21 shRNAs. After resuspension in MethoCult medium and
being plated in 6-plate dishes in duplicate, colonies were counted after
14 days.
For murine experiments, bone marrow cells were seeded in 12-plate dishes
at a density of 73104 cells/well in triplicate in mouseMethoCult medium (Stem
Cell Technologies). Hematopoietic colonies (CFU-Cs) were counted at
7–10 days. For MMC experiments, MMC was added in dilution series of
0–20 nM. To determine the clonal growth of murine HSPCs, cobblestone
area-forming cell (CAFC) assay was performed by a limiting dilution analysis
of bone marrow in microcultures using the bone marrow stromal cell line
FBMD1 (Parmar et al., 2010; Ploemacher et al., 1991). This assay quantifies
a spectrum of hematopoietic cells that is well-validated to compare with
those of other functional assays. Specifically, day 7 and day 14 CAFCs
correspond to early progenitor cells and to CFU-spleen day 12 cells, while
the more primitive HSCs with long-term repopulating ability correspond to
day 28 CAFCs (Ploemacher et al., 1991).
Transplant Assays
For Fancg/ competitive transplant experiments, 33105 to 53105 Lin bone
marrow cells were purified on a column (Miltenyi) and transduced with Ctrl-
Cherry and Trp53-GFP shRNAs, cultured for 3 days, and sorted by FACS,
and an equal number of cells (1 to 1.53105) were IV-injected into the tail of
sublethally irradiated (4.5 Gy) syngenic mice. For parallel experiments, cells
were transduced with Ctrl-GFP or Trp53-GFP shRNAs.
For xenotransplant experiments, 33105 to 53105 human cord blood CD34+
cells were transduced overnight with FANCD2-GFP or tandem FANCD2-
TP53-GFP shRNAs, and 105 cells per mouse were IV-injected into the tail of
sublethally irradiated (2.25Gy) immunodeficient NSGmice. At day 5, transduc-
tion efficacy was measured by analyzing GFP+ cells in a sample of the cells
grown in vitro; mice injected with >50% GFP+ cells for both conditions
were further analyzed. Human cells were quantified in the mouse blood by
HuCD45-PE antibody (Beckman Coulter) staining, and blood GFP+ cells
were quantified. NSG mice (Jackson Laboratory) were housed in the path-
ogen-free animal facility of Institut Universitaire d’He´matologie, Paris. All
experimental procedures were done in compliance with the French Ministry
of Agriculture regulations for animal experimentation.
RNA Extraction and p21 Expression in Human Cells
Dry cell pellets and frozen fetal tissues were extracted using the RNeasy kit
(QIAGEN). RNA samples were reverse-transcribed and the cDNA was
analyzed for p21 and p16 expression by quantitative PCR (RT-qPCR) using
the Taqman method (Applied Biosystems, primers Hs99999142_m1 for p21
and Hs02902543_mH for p16). Gene expression values were normalized to
the expression of the reference genes Beta-glucuronidase (GUS) and Abelson
gene (ABL1) in accordance with international guidelines (Gabert et al., 2003;
Bustin et al., 2009). Levels were indicated relative to the mean expression
value of non-FA control samples, which was arbitrary assigned a value of 1.
Other values were expressed in fold change relative to this calibrator using
the DCT method (log 2 scale).
Large-Scale Gene Expression Analysis
A FA EBV cell line that was transduced with Ctrl or p53 shRNA and treated with
MMC was profiled at several time points using large-scale gene expression
analysis on the GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix).
RNA extraction, labeling, and microarray hybridization were processed for
all samples in the same set of experiments. Supervised analysis of gene
expression was performed with respect to differential expression between
Ctrl and p53 shRNA at 72 hr after MMC treatment. A list of 294 probesets
with false discovery rate <0.05 (188 unique genes) was analyzed for biological
pathways (hypergeometrical test; http://www.broadinstitute.org). Heat-maps
were designed using dChip software and curated genesets (http://www.
broadinstitute.org).
Cell Stem Cell
p53/p21-Mediated Bone Marrow Failure in FAFor bone marrow cell expression analysis in FA patients versus healthy
donors, supervised analysis was performed from publicly available microarray
data files with respect to the absolute value of the differential expression
between FA patients and healthy donors (n = 14 and n = 11, respectively; FA
patients aged >12 years were excluded to limit the possibility of somaticmosa-
icism or clonal evolution). Affymetrix GeneChip probeset summarization,
background correction, and quantile normalization were performed using
the RMA routine as implemented in the ‘‘R’’ Affymetrix package. Probesets
average expressions above six were kept, resulting in 15,171 probesets
(10,154 genes). Four-hundred and sixty-five Gene Ontology genesets were
scored using the Gene Set Enrichment Analysis algorithm (GSEA, http://
www.broadinstitute.org), and corresponding p values were computed using
2,000 permutations. The heat-map of Figure 7 was designed using dChip
software.
Statistical Analyses
Statistical analyses were performed using the Wilcoxon test, Student test,
Chi-squared test for trend in proportions, or the Odd ratio test as indicated
in the legends of the figures.
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